Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.
Follow-Up Questions
What is Odonate Inc (ODTC)'s P/E Ratio?
The P/E ratio of Odonate Inc is N/A
Who is the CEO of Odonate Inc?
Mr. Kevin Tang is the Chairman of the Board of Odonate Inc, joining the firm since 2013.
What is the price performance of ODTC stock?
The current price of ODTC is 0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Odonate Inc?
Odonate Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Odonate Inc market cap?
Odonate Inc's current market cap is $0
Is Odonate Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Odonate Inc, including 0 strong buy, 0 buy, 4 hold, 1 sell, and 0 strong sell
